Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Controller General Of India, Surinder Singh, On India’s Regulatory Overhaul: An Interview With PharmAsia News

This article was originally published in The Pink Sheet Daily

Executive Summary

Singh recounts steps toward Indian first-in-human drug trials.

You may also be interested in...

India’s Drug Watchdog DCGI Speeds Up Regulatory Overhaul; Single Window Clearance to Precede Central Drug Authority

MUMBAI - India's drug regulatory body, the Drug Controller General of India, is set for a comprehensive overhaul of its regulatory and administrative functions

Sweeping Changes In India’s Clinical Trial Laws Could Allow Phase I MNC Studies Under Certain Circumstances

MUMBAI - Conducting clinical trials in India may get a little easier for multinational drug companies. That is because the much-awaited amendments to the contentious "Schedule Y" of India's Drug and Cosmetics Act have moved one step forward

Cipla Questions Patentability Of Roche’s Tarceva In Ongoing Dispute

MUMBAI - The long drawn patent fight in India between Swiss drug giant Roche and Indian generics company Cipla over lung cancer drug Tarceva (erlotinib) is poised for an interesting turn





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts